- Home
- TIL vs PSNL Comparison
TIL vs PSNL Comparison
Compare TIL & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TIL | PSNL |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 872.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TIL | PSNL |
|---|---|---|
| Price | $11.48 | $8.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $100.67 | $10.71 |
| AVG Volume (30 Days) | 58.7K | ★ 1.7M |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $69,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.69 | $2.83 |
| 52 Week High | $42.79 | $11.40 |
Technical Indicators
Market Signals| Indicator | TIL | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 45.71 |
| Support Level | $10.96 | $7.68 |
| Resistance Level | $11.63 | $9.10 |
| Average True Range (ATR) | 0.55 | 0.58 |
| MACD | 0.27 | -0.15 |
| Stochastic Oscillator | 58.80 | 26.06 |
Price Performance
Historical ComparisonAbout TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.